Entering text into the input field will update the search result below

3 Things In Biotech You Should Learn Today: March 1, 2018

Mar. 02, 2018 8:00 AM ETAMGN, GSK, TSRO, BDRX
Zach Hartman profile picture
Zach Hartman


  • Sierra lays the groundwork for collaboration with Tesaro.
  • Amgen gets a new nod from the CHMP for its neutropenia drug.
  • Midatech shows early favor from European regulators in liver cancer.

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Sierra lays the groundwork for collaboration with Tesaro

Company: Sierra Oncology (SRRA) and Tesaro (TSRO)

Therapy: Niraparib and SRA737

Disease: Prostate cancer

News: SRRA announced that it has signed a clinical supply agreement with Janssen to get access to the PARP inhibitor niraparib, made by TSRO. SRRA intends to combine niraparib with its Chk1 inhibitor SRA737 for treatment of metastatic castration-resistant prostate cancer. Combination studies will be conducted on the basis of preclinical findings showing synergistic activity between SRA737 and PARP inhibitors.

Looking forward: We have not yet seen the supporting evidence for combining PARP and Chk1 inhibition. However, SRRA is scheduled to present these findings at this year's AACR meeting, which will take place in mid-April. Until then, it is up to us to speculate on what this move might mean for SRRA and TSRO if the combination proves active. It is probably no accident that TSRO and SRRA are now tied together in clinical development, as opposed to other PARP inhibitor developers.

Overall, this may be a positive move for both companies, but we need to see further supporting evidence.

Amgen gets a new nod from the CHMP for its neutropenia drug

Company: Amgen (AMGN)

Therapy: Pegfilgrastim

Disease: Neutropenia

News: The EMA's CHMP offered a positive opinion on a label modification for pegfilgrastim to include the Neulasta Onpro Kit, which will allow for careful delivery of the drug in a more convenient method for patients. This will mean that patients would not have to return to their infusion center in the days

This article was written by

Zach Hartman profile picture
I am a former PhD scientist-turned-writer focused on cancer education. My writings in Seeking Alpha have been devoted to helping people identify promising investment opportunities in cancer research through commentary of recent events. Readers can learn more about other aspects of cancer research by visiting my site Invest Against Cancer.I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You


Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.